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Background  and  purpose:  Periostin,  a matricellular  protein,  plays  an important  role  in  cardiac  develop-
ment  and  remodeling.  Its expression  proﬁle  and  the  association  with  myocardial  ﬁbrosis  have  not  been
investigated  in  human  failing  hearts.  This  work  aimed  to explore  the  behavior  and  pathologic  signiﬁ-
cance  of  periostin  in signifying  collagen  ﬁbrogenesis  in  human  hearts  from  patients  with  end-stage  heart
failure.
Methods  and  subjects:  Tissues  were  collected  from  heart  transplant  recipients  and the  control  hearts  were
from  unmatched  donors.  Periostin  mRNA  and  protein  were  detected  using  quantitative  real-time  poly-
merase  chain  reaction  and Western  blotting.  Immunohistochemistry  staining  was employed  to  directly
detect  the  protein  level  and  distribution  of  periostin  in heart  tissues.  The  extent  of  myocardial  ﬁbrosis
was  expressed  by the  percentage  of  Masson’s  trichrome  staining.  Gelatin  zymography  was  used  to detect
the activities  of  matrix  metalloproteinase  (MMP)2  and  MMP9.
Results:  A  low  level  of periostin  mRNA  expression  was  found  in  control  hearts  while  not  detectable  at
the  protein  level.  Periostin  mRNA  was  increased  signiﬁcantly  in failing  myocardium  compared  to  that
of  controls.  Periostin  was  distributed  extensively  in left ventricle  and interventricular  septum  of  the
failing  hearts.  Correlation  analysis  showed  periostin  protein  expression  was  positively  associated  with
myocardial  ﬁbrosis  as  well  as  left  ventricular  diastolic  dimension.  The  distribution  and  extent  of periostin
was  consistent  with  that  of  myocardial  ﬁbrosis.  MMP2  activity  has  an  obvious  increase  about  fourfold  in
heart tissues  from  HF patients.  But there  is  no  quantitative  association  with  the  expression  of  periostin.
Conclusions:  Periostin,  the  distribution  and  expression  of  which  were  consistent  with  the  extent  of
myocardial  ﬁbrosis,  might  be a potential  biomarker  of  cardiac  remodeling  in  heart  failure  patients.
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Heart failure (HF) is a complex clinical syndrome arising from
eart or blood vessel abnormalities. It is a common, potentially
eadly condition of the cardiovascular system and the cause of a
arge ﬁnancial burden and cost to the whole world [1]. The devel-
pment of HF is a chronic process of myocardium and cardiac
xtracellular matrix remodeling. There is extensive comprehension
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of cardiac remodeling in the properties of cardiomyocytes. Also,
cardiac extracellular matrix remodeling, especially tissue ﬁbro-
sis, plays a pivotal role in promoting the development of HF. It
might decrease heart compliance and increase the susceptibility to
chamber dilatation and cardiac dysfunction [2,3]. In recent years,
periostin, an extracellular matrix protein, has been proposed as a
regulator of cardiac remodeling, it might be a marker for diagnosis
of the severity of HF, and a therapeutic target for heart failure as
well [4].
Periostin is a 90-kDa secreted protein with 4 repetitive fasci-
clin domains that are similar in sequence to the insect protein
fasciclin-1. It was  reported that periostin plays an important role
in promoting collagen ﬁbrogenesis and regulating atrioventricular
valve maturation during cardiac development [5]. Periostin expres-
sion is minimal in adult hearts but essential to retain the
vier Ltd. All rights reserved.
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iomechanical properties of adult myocardium. It is upregulated
n several heart diseases such as dilated cardiomyopathy (DCM),
yocardial hypertrophy, or myocardial infarction (MI). But the role
f periostin in myocardial regeneration remains controversial [6].
uhn et al. found that periostin induced reentry of adult cardiomy-
cytes into the cell cycle in vitro and in vivo [7], whereas Lorts
t al. did not show an increase in mitosis of myocytes by periostin
8]. Furthermore, it has been demonstrated that periostin might
lso be a regulator of cardiac hypertrophy [9]. Cheng et al. [10]
eported that in patients 3 months after an acute MI,  periostin lev-
ls were negatively correlated with the left ventricular ejection
raction (LVEF), but positively correlated with the left ventricular
nd-diastolic and end-systolic dimensions. Multivariate analysis
howed the periostin levels were independently associated with
he LVEF [10]. Although partial functions of the extracellular matrix
rotein have been deﬁned, the expression proﬁle of periostin
n human failing heart and the associations with myocardium
emodeling have not been established. The present study aimed
o investigate the change in periostin behavior and the patholog-
cal signiﬁcance in signifying collagen ﬁbrogenesis in the human
ailing heart.
aterials and methods
ample collection
Human failing heart tissues were collected from explanted
earts of heart transplant recipients. Control hearts were obtained
rom unmatched donors whose hearts were not suitable to be trans-
lanted. The etiology of HF included idiopathic DCM, hypertrophic
ardiomyopathy (HCM), rheumatic heart disease (RHD), and viral
yocarditis (VMC). The hearts were excised and transported in ice-
old, oxygenated cardioplegic solution, as well as ﬂash frozen in
iquid nitrogen. And then they were kept at −80 ◦C until processing.
ample collection and study design were performed as the pro-
ocols approved by the medical ethical committee, First Afﬁliated
ospital of Nanjing Medical University, PR China.
uantitative real-time polymerase chain reaction
Total RNA was prepared from human myocardial tissues by
sing TRIzol reagent (Invitrogen, Life Technologies, Carlsbad, CA,
SA) as the manual instructed. cDNA was achieved from total RNA
y use of the PrimeScript RT reagent Kit according to the manufac-
urer’s instruction (TaKaRa, Shiga, Japan). And then cDNA was used
s template for quantitative real-time polymerase chain reaction
PCR) with gene speciﬁc primers (periostin-sense TGCCCTGGT-
ATATGAGAATGGAAG, antisense GATGCCCAGAGTGCCATAAACA;
APDH-sense GCACCGTCAAGGCTGAGAAC, antisense TGGTGAA-
ACGCCAGTGGA) and SYBR Green reagent (TaKaRa). Transcription
NAs were quantiﬁed by the comparative cycle threshold method,
ormalized to GAPDH. All real-time PCRs were performed in
riplicate.
estern blotting
Western blotting was used to examine the protein expression
f periostin. A recombinant human periostin protein produced in
ur laboratory was used as positive control [11]. The polyvinyli-
ene ﬂuoride membrane containing periostin was  incubated with
rimary antibodies, anti-periostin (1:1000, Abcam, Cambridge,
K), and then with secondary antibodies, horseradish peroxidase-
onjugated antibody (1:2000, Sigma–Aldrich, St. Louis, MO,  USA).
roteins were revealed using an enhanced chemiluminescence
etection method following to the manufacturer’s instructions
Pierce, Rockford, IL, USA). Semi-quantiﬁcation of the positivelogy 63 (2014) 373–378
bands in the images was  performed using Quantity One software
(Bio-Rad Laboratories, Hercules, CA, USA).
Histological stains and immunohistochemistry
Heart tissues were ﬁxed in 10% phosphate-buffered forma-
lin and embedded in parafﬁn. De-parafﬁned sections with 4 m
thickness were stained according to Masson’s trichrome staining
protocol. The percentage of blue staining indicated the extent of
myocardial ﬁbrosis. Alternatively, the de-parafﬁned sections were
permeabilized by 0.2% Triton X-100 in phosphate-buffered saline
solution. And then they were incubated with anti-periostin anti-
body (ab14041, Abcam) overnight at 4 ◦C and subsequently with
secondary antibodies for 2 h at 37 ◦C. Cell nuclei were stained
with hematoxylin (Sigma–Aldrich). Periostin-positive areas were
quantiﬁed by use of Image-Pro plus (IPP) 6.0 software (Media
Cybernetics, Silver Spring, MD,  USA). Protein level was expressed
as the ratio of periostin-positive area to myocardial tissue area. For
correlation analysis of periostin expression and myocardial ﬁbro-
sis, consecutive sections were obtained for Masson staining and
immunohistochemistry. All images were obtained at 200× mag-
niﬁcation using inverted optical microscope (Eclipse 50i; Nikon,
Corp., Tokyo, Japan).
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
zymography
Protein concentrations were analyzed with a BCA Protein Assay
Kit (Thermo Scientiﬁc, Waltham, MA,  USA). Equal amounts of pro-
tein (20 g/lane) for each sample were mixed with 1 sample buffer
and loaded on a 7.5% polyacrylamide gel incorporated with 0.1%
gelatin for electrophoresis under non-reducing conditions. Follow-
ing electrophoresis the gels were washed twice in 2.5% Triton X-100
for 30 min  at room temperature to remove sodium dodecyl sul-
fate. The gels were then incubated at 37 ◦C overnight in substrate
buffer containing 50 mM Tris–HCl, 10 mM CaCl2, 50 mM NaCl, and
0.05% Brij35 at pH 7.6 and stained for 30 min  with 0.1% Coomassie
brilliant blue. Gelatinolytic activity was visualized as a transparent
band against a blue background. Zymography was measured for
quantiﬁcation analysis by lane density measurement using Image
Lab 2.0 Software (Bio-rad).
Statistical analysis
Data are expressed as means ± SE. Multiple-group compari-
son was  performed by one-way analysis of variance. Comparison
between two  groups under identical conditions was  performed by
the two-tailed Student’s t-test. Spearman’ correlation was used to
assess the relation of periostin levels with left ventricle diastolic
diameter (LVDd) and the extent of myocardial ﬁbrosis. Values of
p < 0.05 were considered statistically signiﬁcant. All statistical anal-
yses were 2-sided and performed using SPSS software (version
12.0; Chicago, IL, USA).
Results
Clinical characteristics
Baseline characteristics of the enrolled patients are summa-
rized in Table 1. Brieﬂy, a total of 15 patients with orthotopic
heart transplantation were included in the study. Of them, 12 were
males and 3 females, with a mean age of 44.5 ± 9.8 years (range,
17–55 years). There were 3 patients in New York Heart Associ-
ation functional class III and 12 in class IV. Among these failing
hearts, 11 were from patients with primary DCM, 2 from HCM, 1
from RHD, and 1 from VMC. These subjects with end stage heart
S. Zhao et al. / Journal of Cardiology 63 (2014) 373–378 375
Table  1
Clinical characteristics of the individuals with heart failure.
Group Sex Age NYHA class HR BP (mmHg) PAP (mmHg) LAD (mm)  LVDd (mm) IVS (mm) LVPW (mm) EF%
DCM M 38 IV 90 100/60 60 51 83 7 8 31.7
F  43 IV 98 95/60 69 46 67 7 6 38.9
M  41 III 100 100/55 60 47 65 8 8 32.5
M  49 IV 80 100/75 52 42 68 10 10 30.4
M  40 IV 102 90/60 55 49 62 8 8 36.2
M  55 III 82 101/65 50 45 77 9 10 36.1
F  48 IV 95 129/60 34 39 74 10 9 33
M  41 III 100 90/60 40 58 86 9 10 26.3
M  57 IV 78 100/80 56 46 72 8 8 34
M  55 IV 68 90/50 72 53 70 9 9 37
M  51 IV 96 100/55 63 55 68 7 7 33.8
HCM  M 28 IV 100 110/70 53 65 52 21 9 36
M  23 IV 118 110/55 75 44 78 15 12 27
RHD  M 52 IV 80 130/60 65 60 97 12 12 29
VMC  F 46 IV 100 95/56 65 52 63 9 9 31
DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; RHD, rheumatic heart disease; VMC, viral myocarditis; M,  male; F, female; HR, heart rate; NYHA, New
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VPW,  left ventricular posterior wall; EF, ejection fraction.
ailure remained severely depressed left ventricle function (LVEF:
2.86 ± 3.69%) as well as markedly enlarged left ventricular cavities
LVDd: 72.13 ± 11.01 mm).
eriostin expression
Quantitative real time PCR showed an obvious increase in
RNA level in failing myocardium compared to that in the con-
rol (Fig. 1A). Protein expression of periostin was  not quantitatively
etected in the ﬁve sections of control hearts either in Western
lotting or immunohistochemical analysis (Fig. 1B–E). Conversely,
arked accumulation of periostin was found within the corre-
ponding parts of failing hearts. Correlation analysis between
rotein expression of periostin and the cardiac dimensional vari-
bles listed in Table 1 showed the target protein level was  only
ositively related with LVDd (r = 0.52, p < 0.05, Fig. 1F). Periostin
evel had no signiﬁcant correlation with systolic blood pressure,
ulmonary artery pressure, left atrial diameter, interventricular
eptum, left ventricular posterior wall, and LVEF (p = 0.25, 0.53,
.15, 0.60, 0.68, and 0.23, respectively).
xpression of periostin and its correlation with myocardial ﬁbrosis
Masson staining showed a relatively disperse distribution of col-
agen ﬁbers in normal hearts and an excessive accumulation of
xtracellular matrix ﬁbrosis consistently in different sections of
ailing heart (Fig. 2A and B). Immunohistochemistry (DAB brown)
nd Masson staining (blue) showed that the location of periostin
as consistent with the ﬁbrosis distribution (Fig. 2C). And the
xtent of periostin expression was highly associated with that of
ollagen ﬁber (r = 0.71, p < 0.01).
MP2  and MMP9  activities
Zymography quantitative analysis showed an obvious increase
bout 4-fold of MMP2  expression in left ventricles of failing heart
ompared to that in the control. Although MMP9  increased, statis-
ical analysis showed no signiﬁcant change between HF and control
earts (Fig. 2D and E). Correlation analysis between protein expres-
ion of periostin and the MMPs  activities showed no signiﬁcant
elation between the periostin and MMP9  or MMP2  (p = 0.43, 0.86,
espectively).ial diameters; LVDd, left ventricle diastolic diameter; IVS, interventricular septum;
Discussion
Matricelluar proteins, which can modulate cell–cell and
cell–matrix interactions, play a pivotal role in cardiac adaptation
and disease [12]. Periostin, as one member of these proteins, was
reported to participate in cardiac development and remodeling
induced by hypertrophy or injury [13,14]. Although its physiologi-
cal and pathological roles have been explored in cultured cells and
animal models [7,9], just as Frangogiannis [12] pointed out, knowl-
edge of the expression of periostin in human cardiophysiological
conditions remains limited and fragmented.
Periostin can interact with other extracelluar matrix (ECM)
molecules such as type I collagen, ﬁbronectin, and tenascin-
C [15,16]. And studies of periostin-deﬁcient mice revealed that
periostin can regulate collagen I and viscoelastic properties of
connective tissue [9,15]. By inducing MMP  production and angio-
genesis, periostin plays an essential role in progression of cardiac
valve degeneration [17]. In MMP9  deletion mice, periostin may  take
part in regulating the age-related myocardial collagen turnover and
deposition [18]. In our study, MMP2  activity was  about fourfold
increased in heart tissues from HF patients. MMP9 activity also
increased but there was  no signiﬁcant difference. This variance
may  be due to the variety of the etiologies of the patients in this
study. Periostin may  be an indicator of ECM synthesis because it
is co-expressed intracellularly with collagen I in the cytoplasmic
endoplasmic reticulum/Golgi [19]. Our data showed there existed
an increased mRNA expression of periostin in failing heart tissues
and protein expression was detected in different parts of the hearts,
especially in left ventricles. However, in the control hearts, we  only
detected mRNA expression of periostin at low levels, and protein
expression was not observed in Western blotting and immunohis-
tochemistry staining. These ﬁndings demonstrated that periostin
might exert important effects on the cardiac remodeling following
the volume or pressure overload in human hearts.
Stansﬁeld et al. found that periostin was closely associated
with the pressure overload-induced left ventricle hypertrophy
either in animal models or humans [20]. Recently, periostin gene
expression in left ventricles was reported to have a positive corre-
lation with systolic blood pressure in patients with left ventricular
hypertrophy induced by chronic renal insufﬁciency [21]. In our
study, correlation analysis showed a positive correlation between
periostin protein level and left ventricular diastolic dimension.
The association was also found between the level of periostin and
myocardial ﬁbrosis in failing heart tissue. This result suggested
376 S. Zhao et al. / Journal of Cardiology 63 (2014) 373–378
Fig. 1. Periostin mRNA and protein expression in failing and control hearts using real time polymerase chain reaction (PCR) (A), Western blotting (B and C), immunohis-
tochemistry staining (D and E), and correlation between periostin level and LVDd (F). Bars represent means ± SE. In non-failing control hearts, a certain degree of periostin
mRNA is detected with real-time PCR. A more than 4-fold periostin mRNA elevation is detected in different parts of failing hearts (A). No periostin protein is detected with
Western  blotting in control hearts but periostin protein was  found in atria, interventricular septum, and ventricles respectively in HF patients. GAPDH protein levels showed
protein loading (n = 15) (B and C). Immunohistochemical staining of periostin protein showed abundant accumulation of periostin within the interstitial space in respective
parts  of HF hearts (D). Note that periostin was localized within the interstitial space. Correlation analysis showed periostin expression was  positively related to LVDd (F).
POSTN,  periostin; CTL, control; HF, heart failure; P, positive sample; IVS, interventricular septum; LA, left atrium; RA, right atrium; LV, left ventricle; RV, right ventricle; LVDd,
left  ventricle diastolic diameter. (200× magniﬁcation), *p < 0.05, **p < 0.01.
S. Zhao et al. / Journal of Cardiology 63 (2014) 373–378 377
Fig. 2. Representative Masson’s trichrome staining revealed obvious interstitial ﬁbrosis in failing hearts (A and B). Blue staining indicates collagen tissue. Consecutive sections
using  Masson’s trichrome staining and immunohistochemistry staining showed an accordance of periostin distribution with interstitial ﬁbrosis (C), (200× magniﬁcation).
G om HF
r ntricu
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r
i
s
ﬁelatin  zymography analysis (D) shows MMP2  and MMP9  activities in LV tissues fr
epresent means ± SE. POSTN, periostin; CTL, control; HF, heart failure; IVS, interve
,  marker; MMP,  matrix metalloproteinase. *p < 0.05, **p < 0.01.
eriostin may  just be a structural remodeling factor, not directly
elated to cardiac function. However, due to the limited cases, the
ssue of whether periostin expression had different patterns in HF
ubjects resulting from various causes needs to be further con-
rmed. (n = 15) and CTL hearts (n = 6). (E) Quantitative analysis of MMP2  and MMP9. Bars
lar septum; LA, left atrium; RA, right atrium; LV, left ventricle; RV, right ventricle;
In conclusion, our ﬁndings indicate that periostin might be
a biomarker of cardiac extracelluar matrix remodeling and was
potentially developed as a factor of myocardial ﬁbrosis followed
by HF. Further investigation should focus on elucidating the
periostin level in blood serum or plasma in HF patients as well as
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